Factbox – Who are Hong Kong’s top biotech IPO hopefuls?

HONG KONG (Reuters) - Biotechs without revenue can apply to list in Hong Kong from Monday under new rules aimed at attracting listings, mostly from China’s fast-developing market. The move is part of a bold effort to rival New York’s Nasdaq, the ... ( read original story ...)

Biotech Startup Innovent Gets $150 Million Booster

a developer of biologically-based anti-cancer drugs known as PD-1 inhibitors, has closed a new $150 million funding round as it head towards an initial public offering (IPO) that could be one of the first under new listing rules being rolled out in Hong Kong. ( read original story ...)